Deutsch
Español
India
Italiano
Français
My Account
My Account
Notifications
Overview
+ New Watchlist
Benzinga Research
Benzinga Pro
Log In
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Get Benzinga Pro
Data & APIs
Events
Marketfy
Premarket
Boost
Advertise
Contribute
Deutsch
Español
India
Italiano
Français
Sign in
Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Government
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Options
Binary Options
Bonds
Futures
CME Group
Global Economics
Previews
Small-Cap
Real Estate
Cryptocurrency
Penny Stocks
Digital Securities
Volatility
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Covey Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Credit Cards
Crypto
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Options
Binary Options
Bonds
Futures
CME Group
Global Economics
Previews
Small-Cap
Real Estate
Cryptocurrency
Penny Stocks
Digital Securities
Volatility
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Covey Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Credit Cards
Crypto
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs
Research
My Stocks
Tools
Free Benzinga Pro Trial
Calendars
Analyst Ratings Calendar
Conference Call Calendar
Dividend Calendar
Earnings Calendar
Economic Calendar
FDA Calendar
Guidance Calendar
IPO Calendar
M&A Calendar
SPAC Calendar
Stock Split Calendar
Trade Ideas
Free Stock Reports
Insider Trades
Trade Idea Feed
Analyst Ratings
Unusual Options Activity
Heatmaps
Free Newsletter
Government Trades
Short Interest
Most Shorted
Largest Increase
Largest Decrease
Calculators
Margin Calculator
Forex Profit Calculator
100x Options Profit Calculator
Recent
Markets
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Stryker
(NYSE:SYK)
Intraday
$337.15
0.30
[0.09%]
After-Hours
$337.15
0
[0.00%]
Get Report
Watch
Perks
Buy
Compare Brokers
$337.15
0.30
[0.09%]
At close: Apr 25
$337.15
0
[0.00%]
After Hours: 4:00PM EDT
Get Report
Watch
Q1 2024 Earnings in 5 days from now on Tue Apr 30th, after the market close
Conference call scheduled in 5 days at 16:30 PM
Click to view the webcast
Overview
News
Earnings
Guidance
Dividends
Analyst Ratings
Insider Trades
Short Interest
Latest News for Stryker Stock (NYSE:SYK)
Stryker Stock (NYSE: SYK)
Categories: All
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
Friday, April 19, 2024
Stryker Unusual Options Activity For April 19
Benzinga Insights
-
6 days ago
Wednesday, April 17, 2024
Here's How Much You Would Have Made Owning Stryker Stock In The Last 20 Years
Benzinga Insights
-
Apr 17, 2024, 3:30PM
Monday, April 15, 2024
RBC Capital Maintains Outperform on Stryker, Raises Price Target to $386
Benzinga Newsdesk
-
Apr 15, 2024, 2:23PM
Thursday, April 11, 2024
TD Cowen Maintains Buy on Stryker, Raises Price Target to $400
Benzinga Newsdesk
-
Apr 11, 2024, 11:57AM
Boston Scientific (BSX) Faces Rising Costs, Competition
Zacks
-
Apr 11, 2024, 6:45AM
Thursday, April 04, 2024
Globus Medical (GMED) Gains From New Launches Amid Macro Issues
Zacks
-
Apr 4, 2024, 1:29PM
Evercore ISI Group Maintains Outperform on Stryker, Raises Price Target to $370
Benzinga Newsdesk
-
Apr 4, 2024, 1:01PM
Wednesday, April 03, 2024
Evaluating Stryker: Insights From 9 Financial Analysts
Benzinga Insights
-
Apr 3, 2024, 1:00PM
Citigroup Maintains Buy on Stryker, Raises Price Target to $406
Benzinga Newsdesk
-
Apr 3, 2024, 11:59AM
Wednesday, March 27, 2024
Price Over Earnings Overview: Stryker
Benzinga Insights
-
Mar 27, 2024, 1:00PM
Looking Into Stryker's Recent Short Interest
Benzinga Insights
-
Mar 27, 2024, 12:30PM
Monday, March 25, 2024
$100 Invested In Stryker 20 Years Ago Would Be Worth This Much Today
Benzinga Insights
-
Mar 25, 2024, 3:30PM
Monday, March 18, 2024
Which Stocks Will Dominate The Future Of Tech? UBS Shares Its Top Picks In AI, Healthtech, Greentech, And Fintech
Benzinga Neuro
-
Mar 18, 2024, 3:14AM
Friday, March 15, 2024
Stryker Unusual Options Activity
Benzinga Insights
-
Mar 15, 2024, 4:01PM
Thursday, March 14, 2024
If You Invested $1000 In This Stock 20 Years Ago, You Would Have $8,100 Today
Benzinga Insights
-
Mar 14, 2024, 12:00PM
Tuesday, March 12, 2024
Options Exercise: William E. Berry, Jr. At Stryker Realizes $4.57M
Benzinga Insights
-
Mar 12, 2024, 11:02AM
Friday, March 01, 2024
Peering Into Stryker's Recent Short Interest
Benzinga Insights
-
Mar 1, 2024, 11:00AM
Thursday, February 22, 2024
$1000 Invested In Stryker 20 Years Ago Would Be Worth This Much Today
Benzinga Insights
-
Feb 22, 2024, 12:30PM
Thursday, February 15, 2024
RBC Capital Reiterates Outperform on Stryker, Maintains $360 Price Target
Benzinga Newsdesk
-
Feb 15, 2024, 11:13AM
Friday, February 09, 2024
$1000 Invested In This Stock 15 Years Ago Would Be Worth $7,900 Today
Benzinga Insights
-
Feb 9, 2024, 10:00AM
Thursday, February 08, 2024
Board Member Of Stryker Makes $100.35M Sale
Benzinga Insights
-
Feb 8, 2024, 10:01AM
Witnessing An Insider Decision, Yin C Becker Exercises Options Valued At $2.01M At Stryker
Benzinga Insights
-
Feb 8, 2024, 10:01AM
Wednesday, February 07, 2024
Board Member At Stryker Exercises Options Worth $1.13M
Benzinga Insights
-
Feb 7, 2024, 10:02AM
Insider Move: Allan C Golston Exercises Options, Realizing $1.11M At Stryker
Benzinga Insights
-
Feb 7, 2024, 10:02AM
Friday, February 02, 2024
If You Invested $1000 In This Stock 10 Years Ago, You Would Have $4,400 Today
Benzinga Insights
-
Feb 2, 2024, 2:00PM
Wednesday, January 31, 2024
Citigroup Maintains Buy on Stryker, Raises Price Target to $362
Benzinga Newsdesk
-
Jan 31, 2024, 4:00PM
Truist Securities Maintains Hold on Stryker, Raises Price Target to $345-Report Released on 30 January 2024
Benzinga Newsdesk
-
Jan 31, 2024, 2:42PM
Why AMD Shares Are Trading Lower? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Avi Kapoor
-
Jan 31, 2024, 1:18PM
RBC Capital Maintains Outperform on Stryker, Raises Price Target to $360
Benzinga Newsdesk
-
Jan 31, 2024, 12:02PM
Roth MKM Maintains Buy on Stryker, Raises Price Target to $348
Benzinga Newsdesk
-
Jan 31, 2024, 11:23AM
Boeing Posts Upbeat Results, Joins Stryker, Automatic Data Processing And Other Big Stocks Moving Higher On Wednesday
Avi Kapoor
-
Jan 31, 2024, 11:02AM
Critical Insights From Stryker Analyst Ratings: What You Need To Know
Benzinga Insights
-
Jan 31, 2024, 11:00AM
Canaccord Genuity Upgrades Stryker to Buy, Announces $360 Price Target
Benzinga Newsdesk
-
Jan 31, 2024, 9:50AM
Wells Fargo Maintains Overweight on Stryker, Raises Price Target to $364
Benzinga Newsdesk
-
Jan 31, 2024, 9:41AM
Stryker shares are trading higher after the company reported better-than-expected Q4 financial results.
Benzinga Newsdesk
-
Jan 31, 2024, 8:29AM
Stryker Expands Prophecy Surgical Planning System
Benzinga Newsdesk
-
Jan 31, 2024, 8:11AM
Tuesday, January 30, 2024
Stryker Stock Gains On Q4 Earnings, 2024 Outlook
Ryan Gustafson
-
Jan 30, 2024, 5:38PM
Stryker: Q4 Earnings Insights
Benzinga Insights
-
Jan 30, 2024, 4:20PM
Stryker Expects 2024 Organic Net Sales Growth Of 7.5%-9.0% And Adjusted EPS Of $11.70-$12.00 (Est. $11.56)
Benzinga Newsdesk
-
Jan 30, 2024, 4:18PM
Stryker shares are trading higher after the company reported better-than-expected Q4 financial results.
Benzinga Newsdesk
-
Jan 30, 2024, 4:17PM
Stryker Q4 Adj EPS $3.46 Beats $3.27 Estimate, Sales $5.82B Beat $5.60B Estimate
Benzinga Newsdesk
-
Jan 30, 2024, 4:13PM
Earnings Scheduled For January 30, 2024
Benzinga Insights
-
Jan 30, 2024, 5:08AM
Monday, January 29, 2024
Earnings Preview For Stryker
Benzinga Insights
-
Jan 29, 2024, 10:01AM
Tuesday, January 23, 2024
Arterial Device-Focused Inari Medical Likely Acquisition Target, Shares Are Attractively Valued: Analyst
Vandana Singh
-
Jan 23, 2024, 2:56PM
Friday, January 19, 2024
How Is The Market Feeling About Stryker?
Benzinga Insights
-
Jan 19, 2024, 9:15AM
Wednesday, January 17, 2024
Strategic Sale: Glenn S Boehnlein Decides To Exercise Options Worth $13.02M At Stryker
Benzinga Insights
-
Jan 17, 2024, 10:01AM
Witnessing An Insider Decision, James Andrew Pierce Exercises Options Valued At $2.37M At Stryker
Benzinga Insights
-
Jan 17, 2024, 10:00AM
Tuesday, January 16, 2024
Uber, Abbott Laboratories, Vertex Pharmaceuticals And More On CNBC's 'Final Trades'
Avi Kapoor
-
Jan 16, 2024, 8:51AM
Friday, January 12, 2024
Navigating 7 Analyst Ratings For Stryker
Benzinga Insights
-
Jan 12, 2024, 3:00PM
RBC Capital Maintains Outperform on Stryker, Raises Price Target to $345
Benzinga Newsdesk
-
Jan 12, 2024, 2:49PM
Show more
Create a Watchlist
FREE: Follow your stocks and cryptocurrencies with the most actionable alerts on the internet.
Click to Get Started
People Also Watch